Else Nutrition Holdings Inc. is poised for significant advantages following recent developments from the U.S. Food and Drug Administration (FDA) regarding infant formula protein standards. On March 10, 2026, the FDA officially included Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance in its regulatory agenda, signaling a shift that could clarify the pathway for plant-based infant formulas like those developed by Else.
The FDA’s updated guidance is expected to enhance regulatory clarity for companies producing novel infant formulas by establishing clearer scientific expectations for protein quality. This is particularly beneficial for Else Nutrition, which specializes in whole-food, plant-based, non-soy, and non-dairy nutrition for infants. With the FDA’s advancements, the uncertainty surrounding the approval process for plant-based formulations may diminish, potentially accelerating Else’s entry into the U.S. market.
Regulatory Clarity and Market Expansion
Historically, the PER rat bioassay has been a recognized method for assessing the biological protein quality in infant formulas. However, existing standards have been criticized as outdated, often leading to confusion for companies introducing innovative protein sources. By advancing the PER guidance, the FDA aims to clarify study designs, endpoints, and expectations surrounding protein quality validation. This increased transparency allows companies like Else to better navigate the regulatory landscape, reducing a significant risk factor associated with market entry.
The U.S. infant formula market, recognized as one of the largest globally, has faced criticism for its lack of diverse protein options. Federal agencies and Congress have emphasized the need for more consumer choices, particularly non-dairy and plant-based alternatives. Else Nutrition highlighted this demand in a statement issued in June 2025, advocating for expanded options in the infant formula market.
The FDA’s work on PER guidance aligns with broader federal initiatives, including Operation Stork Speed, which seeks to modernize infant formula oversight. This initiative aims to update regulatory frameworks and nutrient standards for the first time since 1998, emphasizing modernization and transparency in the approval process for new products.
Strategic Advantages for Else Nutrition
As competitors primarily utilize conventional dairy or soy proteins, the updated PER methodology could grant Else Nutrition a competitive edge. The refined standards will allow the company to showcase the quality of its novel protein matrices, aligning regulatory requirements with modern product formulations. As the regulatory environment becomes more favorable, Else Nutrition is well-positioned to capitalize on industry trends, including:
– Rising demand for clean-label and plant-based nutrition
– Federal efforts to enhance competition and innovation within the U.S. formula market
– Increased regulatory clarity supporting new product approvals
The company believes that a clearer regulatory pathway significantly boosts its chances of entering the multi-billion-dollar U.S. infant formula market. Moreover, the alignment between Else’s plant-based innovation strategy and evolving regulatory priorities enhances its appeal to institutional investors and funds focused on environmental, social, and governance (ESG) criteria.
Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition, commented on the FDA’s progress, stating, “The FDA’s progress on PER guidance is a meaningful inflection point for Else Nutrition. As clarity increases around the scientific and procedural standards required for novel infant formulas, our regulatory roadmap becomes sharper, more predictable, and increasingly aligned with federal efforts to modernize the U.S. formula market.”
For more information on Else Nutrition’s offerings and its innovative approach to early childhood nutrition, visit www.elsenutrition.com.
Else Nutrition Holdings Inc. continues to focus on developing pioneering, clean, and plant-based food products for various age groups, including infants, toddlers, and adults. With its plant-based, non-soy formula, the company provides a clean ingredient alternative to traditional dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, Else has garnered national retailer support and achieved rapid sales growth, receiving numerous accolades along the way.
The company’s products have been recognized with awards such as the “Best Health and Diet Solutions” award at Milan’s Global Food Innovation Summit in 2017, and it was named the #1 Best Seller on Amazon in the New Baby & Toddler Formula category in the Fall of 2020.
As Else Nutrition navigates this evolving landscape, its focus remains on delivering quality nutrition while meeting the growing consumer demand for plant-based options.
